What Travere Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 49 | 124 |
| Total trades | 76 | 221 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 1,218,694 | 2,383,504 |
| Disposed | 1,304,671 | 2,342,185 |
| Net activity | −85,977 | +41,319 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Oct 15 | Open-market sale · S | −78,400 | $55.02 | −$4.31M | 432,886 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Oct 15 | Open-market sale · S | −37,270 | $54.20 | −$2.02M | 511,286 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Oct 15 | Open-market sale · S | −128,065 | $52.97 | −$6.78M | 548,556 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Oct 15 | Exercise / conversion · M | +200,000 | $8.93 | +$1.79M | 676,621 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Oct 15 | Exercise / conversion · M | +43,735 | $26.88 | +$1.18M | 476,621 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Sep 17 | Open-market sale · S | −6,802 | $64.95 | −$442K | 432,886 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Sep 17 | Open-market sale · S | −101,691 | $64.59 | −$6.57M | 439,688 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Sep 17 | Exercise / conversion · M | +108,493 | $23.34 | +$2.53M | 541,379 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sep 17 | Open-market sale · S | −8,282 | $65.07 | −$539K | 117,066 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sep 17 | Exercise / conversion · M | +8,282 | $22.40 | +$186K | 125,348 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Sep 16 | Open-market sale · S | −96,125 | $63.64 | −$6.12M | 432,886 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Sep 16 | Open-market sale · S | −99,716 | $63.26 | −$6.31M | 529,011 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Sep 16 | Exercise / conversion · M | +195,841 | $23.34 | +$4.57M | 628,727 |
| Rote William E. | Chief Research Officer | Sep 16 | Open-market sale · S | −47,746 | $63.61 | −$3.04M | 98,197 |
| Rote William E. | Chief Research Officer | Sep 16 | Open-market sale · S | −65,104 | $63.12 | −$4.11M | 145,943 |
| Rote William E. | Chief Research Officer | Sep 16 | Exercise / conversion · M | +57,500 | $26.88 | +$1.55M | 211,047 |
| Rote William E. | Chief Research Officer | Sep 16 | Exercise / conversion · M | +55,000 | $15.46 | +$850K | 153,547 |
| Rote William E. | Chief Research Officer | Sep 16 | Exercise / conversion · M | +350 | $17.96 | +$6.29K | 98,547 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sep 16 | Open-market sale · S | −79,113 | $63.65 | −$5.04M | 117,066 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sep 16 | Open-market sale · S | −93,604 | $63.25 | −$5.92M | 196,179 |
Loading...